ANI Names Interim CEO As Przybyl Prepares To Step Down
As Company Also Reveals First-Quarter Results
ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.
You may also be interested in...
ANI Pharmaceuticals has been steered by former Akorn head Arthur Przybyl since March 2009. But he will bring the curtain down on his time with the company next month, as the company recruits his replacement ahead of a key branded product launch.
In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.